A synthetic glycopeptide of substance P analogue (SP6-11) with enhanced NK-1 receptor specificity.

A new glycopeptide analogue of substance P (6-11) (SP6-11), namely, N1,6 (beta-D-glucopyranosyl) [Glu6, Pro9]SP6-11, has been synthesized and found to be water soluble. The in vitro biological activity of this glycopeptide was determined for spasmogenic activity in the guinea pig ileum and for potentiation of electrically evoked contractions in the rat vas deferens. Thus, activities on NK-1, NK-2, and NK-3 receptor types have been differentiated by two assays and, in the case of NK-1 and NK-3, receptors in guinea pig ileum (GPI) were assayed using specific pharmacological procedures. The ED50 values for the analogue and reference peptides substance P (SP), neurokinin A(NKA), and neurokinin B (NKB) were determined and potencies relative to SP were calculated. The analogue is three times more potent than the potent NK-1 agonist SP on NK-1 receptors. Moreover, this glycopeptide proved to be as selective for the NK-1 receptor as the specific agonist SPOMe (the methyl ester of substance P).     

Health advertising

The purpose of this work is to make a brief review of the recent history of health advertising, of the legal basis of its control, of experience accumulated and of future perspectives in this field. Reference is made to the most frequent problems relating to the content of the advertising messages and the need is underlined for the Foral Community of Navarra to be able to legislate on the health advertising referring to the Health Centres, Services and Establishments, explicitly delimiting the criteria that will guarantee fulfillment of the principles of truthfulness, exactness, transparency, loyal competition and health protection.     

Gross and Microscopic Findings in Patients Undergoing Microdermabrasion for Facial Rejuvenation

BACKGROUND: Microdermabrasion (MDA) is a new procedure used for the treatment of cosmetic problems, particularly to combat photoaging and intrinsic aging. Though excellent clinical improvement has been well documented, histologic support is limited. OBJECTIVE: To determine if microscopic changes correlate with clinical improvement and to examine the depth of penetration compared to chemical peels. METHODS: Seven women were submitted to five MDA sessions at weekly intervals. Skin biopsies were performed in all of them, before and after the treatment. Clinical and photographic assessments were recorded weekly. Data concerning skin features, including oiliness, thickness, dilated pores, and general appearance, were all assessed. Microscopic improvement of changes associated with cutaneous aging in the epidermis and dermis where all assessed. For statistical analysis, a t-test for small samples was utilized. RESULTS: All the patients showed clinical and microscopic improvement in all of the parameters assessed. The t-test for small samples showed a P <.05. CONCLUSION: MDA is a good alternative for facial rejuvenation. Improvements in both clinical and microscopic parameters are readily demonstrable.     

Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies

Using newer vaccine platforms which have been effective against malaria in rodent models, we tested five immunization regimens against Plasmodium knowlesi in rhesus monkeys. All vaccines included the same four P. knowlesi antigens: the pre-erythrocytic antigens CSP, SSP2, and erythrocytic antigens AMA1, MSP1. We used four vaccine platforms for prime or boost vaccinations: plasmids (DNA), alphavirus replicons (VRP), attenuated adenovirus serotype 5 (Ad), or attenuated poxvirus (Pox). These four platforms combined to produce five different prime/boost vaccine regimens: Pox alone, VRP/Pox, VRP/Ad, Ad/Pox, and DNA/Pox. Five rhesus monkeys were immunized with each regimen, and five Control monkeys received a mock vaccination. The time to complete vaccinations was 420 days. All monkeys were challenged twice with 100 P. knowlesi sporozoites given IV. The first challenge was given 12 days after the last vaccination, and the monkeys receiving the DNA/Pox vaccine were the best protected, with 3/5 monkeys sterilely protected and 1/5 monkeys that self-cured its parasitemia. There was no protection in monkeys that received Pox malaria vaccine alone without previous priming. The second sporozoite challenge was given 4 months after the first. All 4 monkeys that were protected in the first challenge developed malaria in the second challenge. DNA, VRP and Ad5 vaccines all primed monkeys for strong immune responses after the Pox boost. We discuss the high level but short duration of protection in this experiment and the possible benefits of the long interval between prime and boost.